Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI).
Andrea De GiglioLaura MezquitaEdouard AuclinFélix Blanc-DurandMariona RiudavetsCaroline CaramellaGala MartinezJose Carlos BenitezPatricia Martín-RomanoLamiae El-AmartiLizza E L HendriksRoberto FerraraCharles NaltetPernelle LavaudAnas GazzahJulien AdamDavid PlanchardNathalie ChaputBenjamin BessePublished in: Cancers (2020)
Intercurrent steroids during ICI had no detrimental prognostic impact if the indication was unrelated to cancer symptoms.